The aim of this randomized, double-blind, placebo-controlled clinical trial was to determine the efficacy of a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10 (Phototrop®) on the visual functions and fundus alterations in early age-related macular degeneration (AMD). One hundred and six patients with a clinical diagnosis of early AMD were randomized to the treated or control groups. The primary efficacy variable was the change in the visual field mean defect (VFMD) from baseline to 12 months of treatment, with secondary efficacy parameters: visual acuity (Snellen chart and ETDRS chart), foveal sensitivity as measured by perimetry, and fundus alterations as evaluated according to the criteria of the International Classification and Grading System for AMD. The mean change in all four parameters of visual functions showed significant improvement in the treated group by the end of the study period. In addition, in the treated group only 1 out of 48 cases (2%) while in the placebo group 9 out of 53 (17%) showed clinically significant (>2.0 dB) worsening in VFMD (p = 0.006, odds ratio: 10.93). Decrease in drusen-covered area of treated eyes was also statistically significant as compared to placebo when either the most affected eyes (p = 0.045) or the less affected eyes (p = 0.017) were considered. These findings strongly suggested that an appropriate combination of compounds which affect mitochondrial lipid metabolism, may improve and subsequently stabilize visual functions, and it may also improve fundus alterations in patients affected by early AMD.

Keywords:
Age-related macular degeneration, Acetyl-L-carnitine, n-3 fatty acids, Coenzyme Q10, Mitochondria, Clinical trial, Visual field, Visual acuity, Drusen
1.
van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT: The risk and natural course of age-related maculopathy: Follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol 2003;121:519–526.
2.
Bird AC: The Bowman lecture: Towards an understanding of age-related macular disease. Eye 2003;17:457–466.
3.
Delcourt C, Cristol JP, Tessier F, Leger CL, Descomps B, Papoz L: Age-related macular degeneration and antioxidant status in the POLA study. POLA Study Group. Pathologies Oculaires Liées à l’Age. Arch Ophthalmol 1999;117:1384–1390
4.
Mares-Perlman JA, Brady WE, Klein R, Klein BE, Bowen P, Stacewicz-Sapuntzakis M, Palta M: Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch Ophthalmol 1995;113:1518–1523.
5.
Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, Farber MD, Gragoudas ES, Haller J, Miller DT: Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994;272:1413–1420.
6.
West S, Vitale S, Hallfrisch J, Munoz B, Muller D, Bressler S, Bressler NM: Are antioxidants or supplements protective for age-related macular degeneration? Arch Ophthalmol 1994;112:222–227
7.
Mares-Perlman JA, Fisher AI, Klein R, Palta M, Block G, Millen AE, Wright JD: Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am J Epidemiol 2001;153:424–432.
8.
Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. Arch Ophthalmol 2001;119:1417–1436
9.
Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J: Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration. The Veterans LAST Study (Lutein Antioxidant Supplementation Trial). Optometry 2004;75:216–230.
10.
Toescu EC, Myronova N, Verkhratsky A: Age-related structural and functional changes of brain mitochondria. Cell Calcium 2000;28:329–338.
11.
James AM, Murphy MP: How mitochondrial damage affects cell function. J Biomed Sci 2002;9:475–487.
12.
Schon EA, Manfredi G: Neuronal degeneration and mitochondrial dysfunction. J Clin Invest 2003;111:303–312.
13.
Murphy MP, Smith RA: Drug delivery to mitochondria: The key to mitochondrial medicine. Adv Drug Deliv Rev 2000;41:235–250.
14.
Binienda Z, Virmani A: The mitochondriotropic effects of L-carnitine and its esters in the central nervous system. Curr Med Chem Cent Nerv Syst Agents 2003;3:275–282.
15.
Barron MJ, Johnson MA, Andrews RM, Clarke MP, Griffiths PG, Bristow E, He LP, Durham S, Turnbull DM: Mitochondrial abnormalities in ageing macular photoreceptors. Invest Ophthalmol Vis Sci 2001;42:3016–3022.
16.
Liang FQ, Godley BF: Oxidative stress-induced mitochondrial DNA damage in human retinal pigment epithelial cells: A possible mechanism for RPE aging and age-related macular degeneration. Exp Eye Res 2003;76:397–403.
17.
Feher J, Papale A, Tomei M, Balacco Gabrieli C: Mitochondrial damage and protection in retinal dystrophies. ARVO abstract 1194. Invest Ophthalmol Vis Sci 1998;39:S570.
18.
Ferdinandusse S, Denis S, Dacremont G, Wanders RJ: Studies on the metabolic fate of n-3 polyunsaturated fatty acids. J Lipid Res 2003;44:1992–1997.
19.
Cai J, Nelson KC, Wu M, Sternberg P Jr, Jones DP: Oxidative damage and protection of the RPE. Prog Retin Eye Res 2000;19:205–221.
20.
Feher J, Papale A, Mannino G, Gualdi L, Balacco Gabrieli C: Mitotropic compounds for the treatment of age-related macular degeneration: The metabolic approach and a pilot study. Ophthalmologica 2003;217:351–357.
21.
Kerner J, Hoppel C: Fatty acid import into mitochondria. Biochim Biophys Acta 2000;1486:1–17.
22.
Levine J, Panchalingam K, McClure RJ, Gershon S, Pettegrew JW: Effects of acetyl-L-carnitine and myo-inositol on high-energy phosphate and membrane phospholipid metabolism in zebra fish: A 31P-NMR-spectroscopy study. Neurochem Res 2003;28:687–690.
23.
Villa RF, Turpeenoja L, Benzi G, Giuffrida Stella AM: Action of L-acetylcarnitine on age-dependent modifications of mitochondrial membrane proteins from rat cerebellum. Neurochem Res 1988;13:909–916
24.
Leaf A, Xiao YF, Kang JX: Interactions of n-3 fatty acids with ion channels in excitable tissues. Prostaglandins Leukot Essent Fatty Acids 2002;67:113–120.
25.
Uauy R, Hoffman DR, Peirano P, Birch DG, Birch EE: Essential fatty acids in visual and brain development. Lipids 2001;36:885–895.
26.
Simopoulos AP: Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002;21:495–505.
27.
Youdim KA, Martin A, Joseph JA: Essential fatty acids and the brain: Possible health implications. Int J Dev Neurosci 2000;18:383–399.
28.
Clarke SD: Polyunsaturated fatty acid regulation of gene transcription: A molecular mechanism to improve the metabolic syndrome. J Nutr 2001;131:1129–1132.
29.
Nakamura MT, Cho HP, Xu J, Tang Z, Clarke SD: Metabolism and functions of highly unsaturated fatty acids: An update. Lipids 2001;36:961–964.
30.
Papucci L, Schiavone N, Witort E, Donnini M, Lapucci A, Tempestini A, Formigli L, Zecchi-Orlandini S, Orlandini G, Carella G, Brancato R, Capaccioli S: Coenzyme Q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem 2003;278:28220–28228.
31.
Crane FL: Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001;20:591–598.
32.
Yamamura T, Otani H, Nakao Y, Hattori R, Osako M, Imamura H, Das DK: Dual involvement of coenzyme Q10 in redox signaling and inhibition of death signaling in the rat heart mitochondria. Antioxid Redox Signal 2001;3:103–112.
33.
Barzanti V, Battino M, Baracca A, Cavazzoni M, Cocchi M, Noble R, Maranesi M, Turchetto E, Lenaz G: The effect of dietary lipid changes on the fatty acid composition and function of liver, heart and brain mitochondria in the rat at different ages. Br J Nutr 1994;71:193–202.
34.
Pepe S: Mitochondrial function in ischaemia and reperfusion of the ageing heart. Clin Exp Pharmacol Physiol 2000;27:745–750.
35.
Rodriguez de Turco EB, Parkins N, Ershov AV, Bazan NG: Selective retinal pigment epithelial cell lipid metabolism and remodeling conserves photoreceptor docosahexaenoic acid following phagocytosis. J Neurosci Res 1999;57:479–486.
36.
Wang JY, Saito M: Dietary supplementation of n-3 fatty acids and hydroperoxide levels in rat retinas. Free Radic Res 2001;35:367–375.
37.
Furuno T, Kanno T, Arita K, Asami M, Utsumi T, Doi Y, Inoue M, Utsumi K: Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochem Pharmacol 2001;62:1037–1046.
38.
Atamna H, Ames BN, Liu J: Delaying aging with mitochondrial micronutrients and antioxidants. Scientific World J 2001;1(1 suppl 3):81–82.
39.
Seddon JM, Rosner B, Sperduto RD, Yannuzzi L, Haller JA, Blair NP, Willett W: Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol 2001;119:1191–1199.
40.
Smith W, Mitchell P, Leeder SR: Dietary fat and fish intake and age-related maculopathy. Arch Ophthalmol 2000;118:401–404.
41.
Midena E, Degli Angeli C, Blarzino MC, Valenti M, Segato T: Macular function impairment in eyes with early age-related macular degeneration. Invest Ophthalmol Vis Sci 1997;38:469–477.
42.
Hutchings N, Wild JM, Hussey MK, Flanagan JG, Trope GE: The long-term fluctuation of the visual field in stable glaucoma. Invest Ophthalmol Vis Sci 2000;41:3429–3436.
43.
van Leeuwen R, Chakravarthy U, Vingerling JR, Brussee C, Hooghart AJ, Mulder PG, de Jong PT: Grading of age-related maculopathy for epidemiological studies: Is digital imaging as good as 35-mm film? Ophthalmology 2003;110:1540–1544.
44.
Scholl HP, Dandekar SS, Peto T, Bunce C, Xing W, Jenkins S, Bird AC: What is lost by digitizing stereoscopic fundus color slides for macular grading in age-related maculopathy and degeneration? Ophthalmology 2004;111:125–132.
45.
Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R: An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367–374.
46.
Bland JM, Altman DG: Multiple significance tests: The Bonferroni method. BMJ 1995;310:170–171.
47.
Perneger TV: What’s wrong with Bonferroni adjustments. BMJ 1998;316:1236–1238.
48.
Li J, Tso MO, Lam TT: Reduced amplitude and delayed latency in foveal response of multifocal electroretinogram in early age related macular degeneration. Br J Ophthalmol 2001;85:287–290.
49.
Haimovici R, Owens SL, Fitzke FW, Bird AC: Dark adaptation in age-related macular degeneration: Relationship to the fellow eye. Graefes Arch Clin Exp Ophthalmol 2002;240:90–95.
50.
Tolentino MJ, Miller S, Gaudio AR, Sandberg MA: Visual field deficits in early age-related macular degeneration. Vision Res 1994;34:409–413.
51.
Remky A, Lichtenberg K, Elsner AE, Arend O: Short wavelength automated perimetry in age related maculopathy. Br J Ophthalmol 2001;85:1432–1436.
52.
Abdelsalam A, Del Priore L, Zarbin MA: Drusen in age-related macular degeneration: Pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol 1999;44:1–29.
53.
Sunness JS, Johnson MA, Massof RW, Marcus S: Retinal sensitivity over drusen and nondrusen areas: A study using fundus perimetry. Arch Ophthalmol 1988;106:1081–1084.
54.
Tolentino MJ, Miller S, Gaudio AR, Sandberg MA: Visual field deficits in early age-related macular degeneration. Vision Res 1994;34:409–413.
55.
Feher J, Kovacs B, Schvöller M, Kovacs I, Balacco Gabrieli C: Improvement of fundus alterations in early AMD treated with combination of n-3 fatty acids, coenzyme Q10 and acetyl-L-carnitine (Phototrop™). ARVO 2004, abstract 3093.
56.
Johnson PT, Lewis GP, Talaga KC, Brown MN, Kappel PJ, Fisher SK, Anderson DH, Johnson LV: Drusen-associated degeneration in the retina. Invest Ophthalmol Vis Sci 2003;44:4481–4488.
57.
Demaison L, Sergiel JP, Moreau D, Grynberg A: Influence of the phospholipid n-6/n-3 polyunsaturated fatty acid ratio on the mitochondrial oxidative metabolism before and after myocardial ischemia. Biochim Biophys Acta 1994;1227:53–59.
58.
Pepe S, Tsuchiya N, Lakatta EG, Hansford RG: PUFA and aging modulate cardiac mitochondrial membrane lipid composition and Ca2+ activation of PDH. Am J Physiol 1999;276:H149–H158.
59.
Aureli T, Di Cocco ME, Capuani G, Ricciolini R, Manetti C, Miccheli A, Conti F: Effect of long-term feeding with acetyl-L-carnitine on the age-related changes in rat brain lipid composition: A study by 31P NMR spectroscopy. Neurochem Res 2000;25:395–399.
60.
Virmani MA, Caso V, Spadoni A, Rossi S, Russo F, Gaetani F: Action of acetyl-L-carnitine on the neurotoxicity evoked by amyloid fragments on primary rat cortical neurones. Ann NY Acad Sci 2001;939:162–178.
61.
Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF: An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001;20:705–732.
62.
Rungger-Brandle E, Englert U, Leuenberger PM: Exocytic clearing of degraded membrane material from pigment epithelial cells in frog retina. Invest Ophthalmol Vis Sci 1987;28:2026–2037.
63.
Spaide RF, Ho-Spaide WC, Browne RW, Armstrong D: Characterization of peroxidized lipids in Bruch’s membrane. Retina 1999;19:141–147.
64.
Holz FG, Sheraidah G, Pauleikhoff D, Bird AC: Analysis of lipid deposits extracted from human macular and peripheral Bruch’s membrane. Arch Ophthalmol 1994;112:402–406.
65.
Curcio CA, Millican CL, Bailey T, Kruth HS: Accumulation of cholesterol with age in human Bruch’s membrane. Invest Ophthalmol Vis Sci 2001;42:265–274.
66.
Anderson DH, Mullins RF, Hageman GS, Johnson LV: A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134:411–431.
67.
Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH: A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res 2000;70:441–449.
68.
Anderson DH, Ozaki S, Nealon M, Neitz J, Mullins RF, Hageman GS, Johnson LV: Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: Implications for the process of drusen formation. Am J Ophthalmol 2001;131:767–781.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.